MSLP Muscle Pharm Corporation (CE)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report: August 11, 2015

(Date of earliest event reported)

 

MusclePharm Corporation

(Exact name of registrant as specified in its charter)

 

NEVADA		000-53166		77-0664193
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

 

4721 Ironton Street, Building A

Denver, Colorado 80239

(Address of principal executive offices) (Zip Code)

 

(303) 396-6100

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).

 

  

ITEM 7.01

REGULATION FD DISCLOSURE.

 

On August 11, 2015, MusclePharm Corporation posted on its website a company presentation. A copy of the presentation is attached to this report as Exhibit 99.1 and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in such filing.

 

 

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

 

(d)           Exhibits.

 

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

 

Exhibit No.	Description
99.1	MusclePharm Corporation Presentation dated August 11, 2015

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	MUSCLEPHARM CORPORATION
Dated: August 11, 2015
	By:	/s/ Brad J. Pyatt
	Name:	Brad J. Pyatt
	Title:	Chief Executive Officer

 

 

FOR W ARD LOOKING S T A TEMEN T : I n f orm a tion included he r ein co n t ains f o r w a r d looking s t a t eme n t s. F o r w a r d - looking s t a t eme n t s a r e ide n tified b y wo r ds such as ‘ ‘ e xpect , ’ ‘ ‘ plan , ’’ ‘ ‘ will , ’’ ‘ ‘ should , ’’ ‘ ‘ could , ’’ “ a n ticip a t e , ” “ estim a t e , ” and o ther similar e xp r e s sions. F o r w a r d - looking s t a t eme n t s i nv ol v e significa n t ris k s and uncer t ai n ties, including but n o t limi t ed t o the f ollowing: • Our independe n t audi t o r s h av e e xp r e s sed subs t a n tial dou b t about our abili t y t o co n tinue as a going concern, and we h av e a significa n t working capi t al d e ficit; • I f we f ail t o ef f ecti v ely manage our g r o w th, our busine s s and ope r a tions r esul t s could be harmed; • Our disclosu r e co n t r ols and p r ocedu r es a r e in ef f ecti v e, which could r esult in m a t erial mi s s t a t eme n t s in our financial s t a t eme n t s; • I n t ense competition in our indust r y ; • Our r eliance on a f ew major cus t ome r s; • Our r eliance on manageme n t and k e y pe r sonnel; • W e m a y be e xposed t o m a t erial p r oduct liabili t y claims; • Our insu r ance c ov e r age or thi r d par t y indemnific a tion rig h t s m a y n o t be su f ficie n t t o c ov er legal claims or o ther lo s ses th a t we m a y incur in the f u t u r e; • Our i n t ellec t ual p r oper t y rig h t s a r e v aluable and a n y cost t o p r o t ect them could r educe v alue o f our p r oduc t s and b r and; • W e h av e no manu f ac t uring capaci t y and a n ticip a t e co n tinued r eliance on thi r d - par t y manu f ac t u r e r s. In addition, past pe r f ormance is no gua r a n t ee o f f u t u r e pe r f ormance or r esul t s. All s t a t eme n t s or estim a t es made b y MusclePharm, o ther than s t a t eme n t s o f his t orical f act, r el a t ed t o m a tt e r s th a t m a y or will occur in the f u t u r e a r e f o r w a r d - looking s t a t eme n t s. R eade r s a r e encou r aged t o r ead the section e n titled “Risk F ac t o r s" in our December 3 1, 2 0 13 Annual R eport on F orm 10 - K and a n y and all o f our o ther docume n t s filed with the S E C r ega r ding i n f orm a tion about MusclePharm in r espect o f the f o r w a r d - looking s t a t eme n t s he r ein. I n t e r es t ed parties a r e able t o o b t ain copies o f filings co n t aining i n f orm a tion about MusclePharm without cha r ge, a t the S E C ’ s I n t ernet si t e ( h t tp: / / ww w .se c .g o v ). MusclePharm a s sumes no du t y t o upd a t e the f o r w a r d - looking s t a t eme n t s he r ein. D A TE : PRESENTE R : T A G L INE: A ugust 20 1 5 Richard E stalella, Preside n t Real A thletes. Real Scienc e ™

PG. 3 MUSCLEPHARM: FUELING THE ENGINE OF SPO R T™ BUSINESS Our goal is t o se r v e the needs o f all a thle t es, while f ueling the engine o f spor t s f or all ages and gende r s. MusclePhar m ’ s p r oduct lines a r e designed primarily f or specific a thletic use and a thle t es' needs, d a y in and d a y out. Comp r ehensi v e lines o f clinicall y - p r ov en, s a f e and ef f ecti v e nutritional suppleme n t s • A v ailable in mo r e than 1 10 cou n tries and av ailable in 35 , 000+ r e t ail outle t s • MusclePharm B r ands include MusclePharm® Hybrid Serie s ™ and Co r e Serie s ™, Arnold Sch w a rz enegge r ™ Series, and FitMi s s ™ • D ev eloped th r ough a si x - s t age r esea r ch p r oce s s th a t utili z es the e xpertise o f leading nutritional scie n tis t s, doc t o r s and uni v e r sities • 3 0, 000 squa r e - f o o t f acili t y MP Spor t s Science Insti t u t e, with in house R&D t eam led b y D r . Phillip F r ost, Chairman o f T ev a • T r aded under s ymbol M L SP; headquar t e r ed in De nv e r , Colo r ado

PG. 4 2 01 0 $150,000,00 0 $125,000,00 0 $ 11 0,87 7 ,591 $ 1 00,000,00 0 $75,000,000 $6 7 ,055,215 $50,000,000 $25,000,000 $ 1 7 ,212,636 $3,202,687 $ 1 75,000,00 0 $200,000,00 0 $220,000,00 0 2 01 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 15 E $ 1 7 7 ,289,00 0 $2 1 0,000,00 0 $220,000,00 0 BUI L T FROM THE GROUND UP W e a r e an a thle t e ’ s compa n y , run b y a thle t es who a r e pa s sion a t e about c r e a ting the world ’ s best nutritional and spor t s suppleme n t a tion p r oduc t s f or a thle t es • E s t ablished in 2008 • F ounded b y B r ad P ya t t ( f ormer NFL pl ay e r ) and Co r y G r ego r y (Nutrition indust r y leader and t op t r aining e xper t ) • G r ew f r om $3.2M in net r ev enue t o $ 1 7 7 .3 M in fi v e y ea r s

PG. 5 WEL L - E S T ABLISHED BA SE GROWING DI S TRIBUTION NETWORK • Our nutritional suppleme n t s a r e av ailable f or pu r chase in mo r e than 35 , 000 U .S. r e t ail outle t s, 100 online r e t ail outle t s, and mo r e than 1 10 i n t ern a tional cou n tries • P r o vides pl a t f orm t o launch additional p r oduc t s and p r oduct e x t ensions 120 48 K COUNTRI ES RE T AILE RS 100 + ONLINE RE T AILERS

PG. 6 A cco r ding t o the “Nutrition Busine s s Journal , ” The spor t s nutrition & weig h t lo s s mar k et in the Uni t ed S t a t es w as estim a t ed t o be app ro xim a t ely $37 billion in 2 0 1 4 . In r ece n t y ea r s, nutritional suppleme n t companies, anal y s t s, public a tions and o ther indust r y sou r ces h av e r e f e r enced a consis t e n t g r o w th r a t e o f be t ween 6% and 10% annuall y , particularly in t erms o f sales dollar g r o w th. The indust r y is e xpec t ed t o co n tinue t o g r ow a t a 6% t o 9% g r o w th r a t e ov er the p r ojec t ed g r o w th period 2 0 15 - 2 0 1 7 . CAPTURING A L ARGE AND GROWING MARKET 200 7 $20 Billion $40 Billion $60 Billion $80 Billion $ 1 00 Billion $120 Billion 2008 2009 2 01 0 2 01 1 2 0 1 2 2 0 1 3 2 0 1 4 2 0 1 5 2 01 6 2 0 1 7 $ 1 40 Billion $ 1 60 Billion GRO W TH B Y C A T E GO R Y : • The Mar k et is comprised o f Nutrition Ba r s a t 1 2 %, • Spor t s & Ene r gy Drin k s a t 56%, • Spor t s Nutrition Suppleme n t s a t 1 5 %, • W eig ht - L o s s Meal R eplaceme n t s a t 1 1 % and W eig ht - L o s s Pill - F orm Suppleme n t s a t 6%. MARKET TRENDS: • Inc r eased f ocus on fitne s s and healt h y living • Changing consumer beh a vior t o w a r ds new spor t s nutrition p r oduct f orm a t • Desi r e f or s a f e and ef f ecti v e p r oduc t s G L O B AL SPO R T S NUTRITION MARKET 20 0 7 - 2 0 13 PR O J EC TED * D a t a a cco r di n g t o N a t i o n al B u si n e s s Jour n al * * Al t h o u gh spec i f i c da t a f r om t h e f r a g m e nt ed i nt er na t i o n al m ar k e t s i s n o t r e a di l y av ai l ab l e, w e bel iev e simi l ar d e m og r aph i cs, ev e nt s a n d o t h er t r e nd s a f f ect t h e nu tr i t i o n al supp l e m e n t m ar k e t i nt er na t i o n al l y .

PG. 7 • E f f ecti v e Science - Based P r oduc t s • Our p r oduc t s a r e the r esult o f a si x - s t age p r oce s s i nv olving r ecogni z ed nutrition scie n tis t s, doc t o r s and p r o f e s sional a thle t es a t our MP Spor t s Science Insti t u t e • E v e r y p r oduct is a f ormul a tion th a t we, as f ormer p r o f e s sional a thle t es, beli ev e in and use ev e r y d a y OUR PRODUC TS: INCRE A SING MARKET SHARE LE G A C Y B UILD Y O UR R E A L A T H L E T ES. R E AL S C I E N CE. ™

PG. 8 T A G LINE R eal Science. R eal A thle t e s ™ T ARGET A UDIENCE • Prima r y Mar k et: Male 18 - 35 age g r oup • Seconda r y Mar k et: Male 3 5 + age g r oup L A UNCHED 2008 NUMBER OF PRODUC T S 15 PRODUC T S INC L UDE • Amin o 1 ™ • Armo r - V ® • A s sault • B a t tle F uel X T ™ • • • • Comb a t ® MuscleGel ® Sh r ed M a trix® R e - Con® AW ARD S • B r and Of Y ear • Glu t amine Of Y ear ( Glu t amin e ) • • • • • • P r e - W or k out o f Y ear ( A s saul t ) New Suppleme n t o f Y ear ( A s saul t ) P ac k aging o f Y ear Me n ’ s Support Suppleme n t o f Y ear (B a t tle F uel X T ) Rising S t ar o f Y ear RTD o f Y ear (MuscleGel) INTERN A TIONAL AW ARDS • B r azil: 2 0 13 B r and Of Y ear Major Sales G r o w th A w a r d * 2 0 1 4: B r and Of Y ea r , P r e - W or k out Of Y ear ( A s saul t ) DOME S TIC DI S TRIBUTER E u r opa Spor t s RE T AILER S • Ball y ’ s • Cos t co • Dic k s Sporting Goods • GNC • • • V i t amin Shoppe V i t amin W orld 2 4 Hour Fitne s s E - COMMERCE • Ama z on.co m • • BodyBuilding.co m V i t aCost.com INTERN A TIONA L 1 10 Cou n tries MUSCLEPH ARM HYBRID & CORE SERIES BRAND MES SA GE Scie n tificall y - ad v anced, pe r f ormance - dri v en suppleme n t s th a t c ov er all bases f or a thle t es and their wor k out needs. This line o f inn ova ti v e, Uni v e r si t y - t es t ed p r oduc t s help f uel a thle t es s a f ely b y inc r easing S t r ength, Endu r ance, H y d r a tion, R ec ov e r y , and ov e r all a thletic P e r f ormance. MP Hybrid Series p r oduc t s li k e A s sault, Amin o 1 and Comb a t® co n t ain ing r edie n t s th a t deli v er clinicall y - p r ov en pe r f ormance . MP Co r e p r oduc t s, such as B C A A 3 : 1 : 2 , CLA Co r e and Fish Oil, balance the e s se n tials t o meet the d a y - in and d a y - out demands o f a thle t es . PG. 8

PG. 9 T A G LINE S TRONG IS THE NEW SE X Y® T ARGET A UDIENCE • Prima r y Mar k et: F emale 25 - 45 age g r oup • Seconda r y Mar k et: F emale <25 age g r oup L A UNCHED 2 0 13 NUMBER OF PRODUC T S 8 PRODUC T S INC L UDE • FitMi s s Bur n ™ • FitMi s s Balanc e ™ • FitMi s s Cleans e ™ • FitMi s s Delig h t® • FitMi s s I gni t e ™ • FitMi s s T on e ™ • FitMi s s T y t e ™ • FitMi s s Z - Sli m ™ AW ARDS Nomin a t ed f or W ome n ’ s P r oduct o f Y ear (Delig h t®) DOME S TIC DI S TRIBUTER E u r opa Spor t s RE T AILERS • Ball y ’ s • Dic k s Sporting Goods • GN C • W alg r een s • V i t amin Shoppe • V i t amin W orld • 2 4 Hour Fitne s s E - COMMERCE • Ama z on.co m • Bodybuilding.co m • Drug St o r e.co m • V i t acost.com INTERN A TIONAL 35 Cou n tries FITMISS BRAND MES SA GE: Designed, dosed, and f ormul a t ed specifically f or the acti v e woma n ’ s li f es t yle utilizing clinically p r ov en ing r edie n t s th a t c ov e r s the r ange o f bu s y wome n ’ s needs, f r om including weig h t lo s s, multi - vi t amins, p r o t ein sha k es, de to x, skin ca r e, and p r e - wor k out ene r gy mi x es. Our doc t o r s f ormul a t ed these our p r oduc t s f or “he r ” women who also f ollow r egular wor k out r outines. A s working out and p r oper nutrition a r e the k e y s t o looking good and f eeling good.

PG. 10 T A G LINE Build Y our L egac y ™ T ARGET A UDIENCE: • Prima r y Mar k et: Male 18 - 45 age g r oup • Seconda r y Mar k et: Male 4 5 + age g r oup L A UNCHED 2 0 13 NUMBER OF PRODUC T S 7 PRODUC T S INC L UDE • I r on CR E3 ™ • I r on Cu t s ™ • I r on D r ea m ™ • I r on P ac k ™ • I r on Pum p ™ • I r on Ma s s ™ • I r on Wh ey ™ AW ARDS N /A DOME S TIC DI S TRIBUTER E u r opa Spor t s RE T AILERS • Ball y ’ s • Dic k s Sporting Goods • GNC • Gold ’ s Gym • V i t amin Shoppe • V i t amin W orld • 2 4 Hour Fitne s s • W inn Dixie E - COMMERCE • Ama z on.com • Bodybuilding.com • V i t acost.com INTERN A TIONAL 90 Cou n tries ARNOLD SCH W ARZENE GGER SERIES BRAND MES SA GE Cu t ting - edge p h y sique suppleme n t s t ailo r ed f or the fitne s s and bodybuilding e n thusias t s. Th e y a r e comprised o f p h y sique - enhancing ing r edie n t s li k e p r o t ein gaine r s, muscle builde r s, multivi t amins, and nitric o xide boos t e r s. Arnold Sch w a rz enegger wor k ed side - b y - side with MusclePharm® ’ s world - r enowned scie n tific t eam t o c r e a t e a line o f nutritional suppleme n t s th a t n o t only car r y his iconic name, but r ep r ese n t his li f elong commitme n t t o fitne s s and bodybuilding as well. PG. 10

PG. 11 CORE S TREN G THS 1. PRODUCING T OP QUALITY PRODUCTS 2. BA CKED B Y REAL A THLETES – REAL SCIENCE 3. CU ST OMER EXPERIENCE - UNM A T CHED CONNECTION WITH CU ST OMERS

PG. 12 E S T ABLISHING TRU S T : PRODUCING T OP QUALITY PRODUCTS • Insti t utional R e view Boa r d - app r ov ed clinical trials in - house a t the 3 0, 000 sq. ft. MusclePharm Spor t s Science Insti t u t e • Quali t y co n t r ol and scie n tific t eam comprised o f 20 scie n tis t s, pharmacis t s and doc t o r s • Scie n tific A dviso r y Boa r d: O v e r seen b y Scie n tific A dviso r y Boa r d led b y D r . R oscoe Moo r e, a f ormer A s sis t a n t U .S. Su r geon Gene r al and U .S. F ood and Drug A dminist r a tion Di r ec t o r , and D r . Phillip F r ost, chairman o f TE V A Pharmaceuticals. • A dditional clinical s t udies a r e pe r f ormed t o v alid a t e s a f e t y , ef ficacy and pe r f ormance th r ough the Uni v e r si t y o f North Ca r olina a t Chapel Hill, W ichi t a S t., A uburn Uni v e r si t y and o ther uni v e r sities • All p r oduc t s a r e certified b y I n f ormed Choice who is the world leader in Banned Subs t ance T esting ensuring th a t final p r oduct does n o t co n t ain a n y subs t ances banned b y sporting o r gani za tions globally

PG. 13 BUILDING THE BRAND: THE A THLETES COM P ANY ORGANIZ A TIONS: • O f ficial Suppleme n t o f U F C, now in ov er 800M homes Globally • O f ficial Suppleme n t o f U S A Wr estling • B r and Amba s sado r s: Arnold Sch w a rz enegge r , Collin K aepernick, Jen Sel t e r , T iger W oods

PG. 14 EARNING L O Y A L T Y : CONNECTING WITH CU ST OMERS W e h av e built one o f the st r ongest social communities in the indust r y • Daily W or k ou t s, T r aining A dvice and Diet Plans b y our A thle t es and MP Doc t o r s • Social Media & Cus t omer Command Ce n t er in Columbus, Ohio • P r o vides daily wor k ou t s, t r aining advice, diet plans, meals, r ecipes MUSCLEPH ARM 720K FITMIS S 660 K 340 K 290 K 300 K 1 40 K

PG. 15 CRE A TIN G A W AREN ESS: • O f ficial suppleme n t sponsor o f the Ultim a t e Fig h ting Championship • Sponso r ed ov er 100 U F C fig h t e r s including Ande r son Sil v a, Jon “Bone s ” Jones, Qui n t on “ R ampag e ” Jac k son, Cl a y Guida, and R ashad E v ans

PG. 16 GENER A TING BU ZZ

PG. 17 EX P AND CURRENT PRODUCT LINE • MusclePharm b r and will be launching ov er 75 new p r oduct of f erings in 2 0 1 4 • The FitMi s s b r and will be launching ov er 20 new p r oduct of f erings in 2 0 1 4 • The Arnold b r and will be launching ov er 40 new p r oduct of f erings in 2 0 1 4 GROW DI S TRIBUTION N A TIONAL L Y AND G L O B AL L Y • L ev e r age r e t ail and v endor partne r ships • Co n tinue t o b r and the MP name INCRE A SE AW ARENESS • Bring on additional a thle t e s / t ale n t t o mar k et new p r oduc t s • Co n tinue endo r seme n t s, sponso r ships and p r o viding samples th r ough g r a s s r o o t s mar k eting. DEVE L OP AND INTRODUCE NEW BRANDS • L ev e r age Bio Z one acquisition t echnology • Co n tinue t o l ev e r age distribution ne t work and d ev elop new channels GROWING THE COM P AN Y : CORE S TR A TEGIES

PG. 18 • A dded T iger W oods and John n y Manziel as our newest b r and amba s sado r ’ s • S t r engthened r e t ail p r esence with GNC • Published double – blind placebo – co n t r olled clinical trial co n firming s a f e t y and ef ficiency o f M P ’ s p r e - wor k out A s saul t ™ RECENT DEVELOPM ENTS

PG. 19 ENHANCING PROFI T ABILITY BUILDING V ALUE DRIVE REVENUE GRO W TH AND C A P TURE MARKET SHARE • Co n tinue building the b r and with new and ex citing p r oduc t s • High r e t e n tion with cus t ome r s th r ough one o f kind cus t omer e xperience • A dditional channels o f distribution • A dditional doo r s and mar k e t s ENHANCE PROFI T ABILI T Y B Y EX P ANDING MARGINS • Imp r ov e supply chain: Anal y z e inc r eme n t al v olume and o p timi z e pu r chase pricing • I n t r oduce p r oduct and line e x t ensions in spor t s nutrition a r eas th a t command higher ma r gins • V ertical i n t eg r a tion o f manu f ac t uring with - in the n e x t 18 mo n ths. 2 01 1 EP S GROSS MARGINS NET REVENUES 2 0 1 2 2 0 1 3 2 0 1 4 * $ 1 7 ,212,6 36 13.8 % ($70. 3 ) *ESTIM A T ED ($13. 0 ) ($2.5 ) $(1.25 ) 21 . 4 % 29.9 % 31.6 % $6 7 ,055,21 5 $ 11 0,8 7 7 ,5 9 1 $ 1 7 7 ,289,00 0 2 0 15 * $ ( 0 . 75 ) 3 1 % - 33% $2 1 0 M - $220 M

PG. 20 S TRONG GROW TH TRANSITIONING T O PROFI T ABILITY 0 2 0 14 2 0 15 2 0 13 2 0 12 2 0 1 1 NET REVENUE S GROSS MARGINS EPS $ 1 7 ,212 , 636 $6 7 , 055, 215 $1 1 0 ,8 7 7 , 5 9 1 $ 1 7 7 ,28 9, 000 $210M - $220M 1 3 .8 % 21 . 4 % 2 9 .9 % 3 1 . 6 % 3 2 % - 33% - $ 70 . 3 - $ 1 3. 0 - $2. 5 - $ 1.2 5 - $ 0 . 7 5

PG. 21 20 1 4 GLO B A L CHANNEL S ALES $ 1 7 7 MILLION SP E CIA L T Y INTERN A TIO NAL FD M 45 % 40 % 15 %

PG. 22 MUSCLEPH ARM TEAM BRAD P Y A T T CHIEF EX E CUTIVE OFFICER • F ounded MusclePharm® in 2008 a f t er pl a ying p r o f e s sional f o o tball f or s ev en y ea r s, the majori t y with the Indianapolis Col t s • Fi r sthand e xperience with t aking suppleme n t s t o enhance pe r f ormance • Bac k g r ound in kinesiology and ex e r cise science RICHARD E S T ALELLA PRESIDENT • Mo r e than 30 y ea r s o f e xperience, with e x t ensi v e knowledge in supply chain, r e t ail, distribution and w a r ehouse ope r a tions • F ormer Senior V ice P r eside n t o f Ope r a tions a t Arbonne I n t ern a tional, a skin ca r e and wellne s s p r oduc t s compa n y • F ormer Senior V ice P r eside n t o f W a r ehouse Ope r a tions o f O f fice Dep o t, whe r e he es t ablished ma n y o f the compa n y ’ s r e t ail mar k e t s, along with i t s n a tionwide distribution ce n t er ne t work JOHN PRICE CHIEF FINANCIAL OFFICER • Cur r e n t Chairman o f Disclosu r e Commi tt ee and Chi e f Risk Manageme n t O f fice r . • Ex t ensi v e e xperience a t public and pri va t e companies; including V ice P r eside n t o f Finance - North America a t Ope r a S o f tw a r e, V ice P r eside n t o f Finance and Corpo r a t e Co n t r oller a t G C T Semiconduc t or and T e s se r a T echnologies. • F ormer Ernst & Y oung LLP and is a Certified Public A ccou n t a n t ( cur r e n tly inacti ve ). JIM GREENWELL CHIEF OPER A TING OFFICER • Mo r e than 25 y ea r s o f manageme n t e xperience • F ormer MusclePharm Boa r d Member • F ormer V ice P r eside n t, V oice P r oduc t s f or I n t ellig r a t ed, Chairman and C E O o f the D a tria S y s t ems and Senior V ice P r eside n t, Sales and Mar k eting f or DecisionOne CO R Y GR E GO R Y EVP BRAND MAN A GEMENT - CO - F OUNDER • Ex t ensi v e e xperience and v arious accolades within s ev e r al a r eas o f the fitne s s indust r y • F e at u r ed on the c ov er o f t op fitne s s magazines, including Fitne s s RX and Inside Fitne s s • E x e r cise Specialist certific a t e f r om Columbus S t a t e, NE S T A nutrition coach certified, W es t side Barbell certified, C r o s sFit L ev el 1 t r ainer • A dvisor on Arnold Sch w a rz enegger Fitne s s A dviso r y Boa r d • F ormer unde r g r ound coal mine r , G r ego r y opened his own gym b y the age o f 20

PG. 23 SCIENTIFIC ADVISO R Y B O ARD DR. ERIC SERRAN O , M. D . M. D . – CHIEF F ORMUL A T OR & MEDI C AL A D VISOR • Conside r ed one o f the leading spor t s nutrition doc t o r s in the cou n t r y • Clie n t s include a wide ar r a y o f a thle t es f r om the NFL, NHL, and MLB; as well as eli t e am a t eur a thle t es • F ormul a t ed nume r ous nutritional suppleme n t s f or some o f the leading nutritional companies on the mar k et, including MusclePharm DR. ROSCOE M. MOORE, JR. CHIEF SCIENTIFIC DIR ECT OR • F ormer U .S. A s sis t a n t Su r geon Gene r al • Se r v ed with the Uni t ed S t a t es Departme n t o f Health and Human Se r vices (HH S ) • Principal pe r son r esponsible f or global d ev elopme n t support within the O f fice o f the Sec r e t a r y , HHS, with prima r y emphasis on Co n tine n t al Af rica and o ther le s s d ev eloped cou n tries o f the world DR. PHILLIP FRO S T , M. D . A D VISOR • Succe s sf ully f ounded s ev e r al pharmaceutical companies and ov e r see the d ev elopme n t and comme r ciali za tion o f a multi t ude o f pharmaceutical p r oduc t s • Chairman o f the Boa r d o f T ev a Pharmaceutical; Chairman o f the Boa r d o f L adenbu r g Thalmann Financial; Chairman o f the boa r d o f di r ec t o r s o f PRO L OR Bi o t ech; Di r ec t or o f Castle B r ands • F ormer Chairman o f the Departme n t o f Derm a t ology a t Mt. Sinai Medical Ce n t er o f G r e a t er Miami, Miami Beach, Chairman o f the Boa r d o f Di r ec t o r s o f K e y Pharmaceuticals • P r e viously se r v ed as Di r ec t or o f Co n tinuca r e Corpo r a tion, North r op Grumman Corp., I de a tion A cquisition Corp., P r o t alix Bio The r apeutics, In c ., and S a f e S ti t ch Medical In c ., and as G ov ernor and Co - V ice - Chairman o f the American S t ock E x change (now N Y SE Am e x). DR. S TEPHEN LI U , M. D . A D VISOR • Senior A dvisor f or The F r ost G r oup, and f or Cal Insti t u t e o f T echnology ( Cal T ech) Medical Engineering, whe r e he v e t s t echnology and i nv estme n t s f or the g r oups. • He has helped s ev e r al companies go public as well as e n t er i n t o st r a t egic partne r ships • Member o f the Boa r d o f Di r ec t o r s a t Ca r doMedical, Chairman a t I F G Health G r oup, P artner a t P acRim Capi t al G r oup, and boa r d member a t Cu r e Pharmaceutical

PG. 24 PG. 24 • L eading the industry with science - based p r oduc t s t es t ed f or s a f e t y and e f ficacy • L a r ge and g r owing mar k et, with inc r easing ado p tion o f MusclePharm b r ands • P r oduc t s c r e a t ed b y a thle t es f or a thle t es and p r om o t ed b y a thle t es • F ocus on cus t omer s a ti s f action and b r and loy al t y • No close competi t or in spor t s nutrition with the b r and awa r ene s s o f MusclePharm • St r ong g r o w th t r ajec t ory and p r ojec t ed t r ansition t o p r o fi t abili t y • Manageme n t t eam and adviso r s with unpa r alleled industry e xpertise WHY INVE S T